Agios Pharmaceuticals Inc (STU:8AP)
€ 56 0 (0%) Market Cap: 3.20 Bil Enterprise Value: 2.30 Bil PE Ratio: 5.18 PB Ratio: 2.06 GF Score: 28/100

Agios Pharmaceuticals Inc at Canaccord Genuity Growth Conference (Virtual) Transcript

Aug 13, 2020 / 05:00PM GMT
Release Date Price: €34.15 (-0.90%)
John Lawrence Newman
Canaccord Genuity Corp., Research Division - Principal & Senior Healthcare Analyst

Hi, everybody. Welcome back to the 40th Annual Canaccord Genuity Growth Conference, which is being held virtually this year. I apologize for a little bit of a delay here for some technical issues. But we're very excited to have Agios with us today, a company that many investors know very well. So we're excited to have the CFO of Agios, Andrew Hirsch; as well as Chief Medical Officer; Dr. Chris Bowden with us today. So Andrew and Chris, welcome.

Andrew Hirsch
Agios Pharmaceuticals, Inc. - Former CFO & Head of Corporate Development

Great. Thanks, John. Thanks for having us.

Questions & Answers

John Lawrence Newman
Canaccord Genuity Corp., Research Division - Principal & Senior Healthcare Analyst

Super. Well, if it's okay, I just wanted to start out with a question about your sickle cell program, which has gotten a lot of attention as of late. It's being closely followed. We know that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot